Healthcare is arguably defined by a continual push for better mousetraps, and LipoScience (LPDX) may have a better mousetrap for diagnosing and characterizing heart disease. Not only does LipoScience provide information to doctors that other systems currently on the market do not, it does so with a platform that offers meaningful potential value for the hospital or lab using it. Diagnostics is a very crowded market and it is absolutely essential that LipoScience broaden its array of assays, but this looks like a small med-tech well worth keeping an eye on today.
It's Counting Particles That Counts
I'll talk about LipoScience's technology approach in a moment, but for now the biggest relevant detail to this company is what...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: